Thomson Reuters, a distinguished brokerage company, has placed a 52-week price target of $95.71 on Eli Lilly and Company (NYSE:LLY) shares after it surveyed top market analysts. Calculating estimated earnings after taking into consideration different elements, it is predicted to come at $3.57 for the next fiscal and $N/A for underway quarter. Valuation Estimates Analysts take into account the price to earnings ratio to estimate the firm’s valuation. This ratio, which is also called as the P/E ratio evaluates the company on relative expense factor. The formula to calculate ratio is stock’s latest price/ per share earnings. The P/E ratio of Eli Lilly and Company (NYSE:LLY) stands at 36.38. Analysts also work out Price/Earnings Growth ratio in an attempt to estimate the valuation of a firm. This ratio commonly known as the PEG ratio implies the stock’s valuation compared to earnings growth potential. Investors look to invest in the stocks with a lower PEG ratio. For Eli Lilly and Company Common St, the PEG ratio for coming 3-5 years is 1.77. Technical Analysis The technical analysis highlights that Eli Lilly and Company Common St current price is trading $3.89 points away +5.18% from $75.06, which stands as the 50-day moving average of the firm. The stock’s 200-day MA is $76.39 and, for now, the stock price is trading $2.56 or +3.35% away from that point. The 52-week high of Eli Lilly and Company (NYSE:LLY) was $92.85 while lowest point recorded in 52-week was $67.88. It implies if stock price makes a movement of over $-13.90, it will record a new 52-week high. In the case of $+16.31% points drop, it will touch a new 52-week low.
1 Chart Pattern Every Investor Should Know